Dyne Therapeutics (DYN) Competitors

Dyne Therapeutics (NASDAQ:DYN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.

Does the MarketBeat Community prefer DYN or GRFS?

Grifols received 306 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 77.19% of users gave Dyne Therapeutics an outperform vote while only 56.09% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Dyne Therapeutics	Outperform Votes 44 77.19%	Underperform Votes 13 22.81%
Grifols	Outperform Votes 350 56.09%	Underperform Votes 274 43.91%

Which has more risk & volatility, DYN or GRFS?

Dyne Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Which has preferable earnings & valuation, DYN or GRFS?

Grifols has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$235.94M	-$3.35	-3.42
Grifols	$7.21B	0.69	$64.20M	$1.17	6.21

Do institutionals & insiders have more ownership in DYN or GRFS?

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media favor DYN or GRFS?

In the previous week, Dyne Therapeutics had 3 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Dyne Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 1.18 beat Dyne Therapeutics' score of -0.06 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is DYN or GRFS more profitable?

Grifols' return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-57.46%	-51.62%
Grifols	N/A	N/A	N/A

Do analysts rate DYN or GRFS?

Dyne Therapeutics currently has a consensus price target of $47.46, indicating a potential upside of 314.51%. Given Dyne Therapeutics' higher possible upside, research analysts clearly believe Dyne Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.07
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Summary

Grifols beats Dyne Therapeutics on 9 of the 17 factors compared between the two stocks.